Compare APC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | GERN |
|---|---|---|
| Founded | 2025 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.3M | 808.3M |
| IPO Year | N/A | N/A |
| Metric | APC | GERN |
|---|---|---|
| Price | $19.33 | $1.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $21.75 | $2.17 |
| AVG Volume (30 Days) | 210.6K | ★ 14.8M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.47 | $26.91 |
| Revenue Next Year | $4.20 | $43.75 |
| P/E Ratio | $25.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.08 | $1.04 |
| 52 Week High | $21.72 | $2.01 |
| Indicator | APC | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 65.05 |
| Support Level | $17.55 | $1.44 |
| Resistance Level | $19.43 | $1.72 |
| Average True Range (ATR) | 0.75 | 0.09 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 74.88 | 68.06 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.